A Phase 4 interventional study of Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) in Staphylococcus Aureus Bacteremia, sponsored by Intermountain Health Care, Inc.. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Intermountain Health Care, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Bacteremia with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Bacteremia · United States.
Among the 79 studies in Bacteremia with a site in United States, this one is the 3rd largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 4, and was the 77th registered.
298 studies on the registry are indexed under Bacteremia; 50 are open to participants now.
Browse Bacteremia studies →6 of the 79 studies in Bacteremia with a site in United States are open now. Recruiting first, the newest first:
Deepull Diagnostics S.L. · Sites in United States, France, Germany and 2 more countries
Wake Forest University Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
The University of Texas Health Science Center, Houston · Sites in United States, Argentina, Chile and 2 more countries
Ages 18+
West Virginia University · Sites in United States
Ages 18+
Milton S. Hershey Medical Center · Sites in United States
Ages up to 12 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Bacteremia studies recruiting now, 31 (79%) set no upper age limit and 4 (10%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 8 · Phase 4 11
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,096 is above the median of 156 across 156 interventional studies indexed under Bacteremia.
Median enrollment 85 across the 45 interventional studies, 470 across the 32 observational. Of the 64 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 79 have an industry lead sponsor. The 10 most frequent:
Intermountain Health Care, Inc. is the lead sponsor of 120 studies on the registry; 15 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 3 (33%) have results posted.
Intermountain Health Care, Inc. has 1 study filed under Bacteremia — fewer than ten, so there is no comparison to draw.
4 of the studies in Bacteremia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07859852Deepull Diagnostics S.L.Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test | 2027-04 |
| NCT01879761University of ChicagoImmune Resolution After Staphylococcus Aureus Bacteremia | 2027-06 |
| NCT07148960West Virginia UniversityDoes Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? | 2027-07 |
| NCT05721781Wake Forest University Health SciencesReducing Risk for Infective Endocarditis | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 79 studies in Bacteremia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.
Staphyloccocus aureus bacteremia (SAB) is a common infectious disease condition in hospitalized patients which is associated with significant morbidity, excessive costs, and high mortality, despite effective antibiotic therapy. This pragmatic study is designed to test the hypothesis that outcomes in adults hospitalized with SAB will be improved by using combination antibiotic therapy (CAT) as early, targeted therapy in a high-risk subgroup. A group of patients identified early in their course as meeting at least one high-risk criterion who have no contraindications will be treated with one of two antibiotic strategies commonly used within usual care, namely: 1) antibiotic monotherapy or 2) combination antibiotic therapy, depending on the random assignment for each hospital, each month. Low-risk patients will be treated per usual care. Data from all patients admitted to participating hospitals with SAB will be included in the analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Initial positive blood culture with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA), collected:
Exclusion Criteria:
Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MSSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy
Drug: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) · Drug: Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)
Patients with methicillin-resistant S. aureus bacteremia (MRSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MRSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy
Drug: Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) · Drug: Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.
Vancomycin or daptomycin, per discretion of the treating physician
Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem
Daptomycin plus ceftaroline
Desirability of Outcome Ranking (DOOR)
The DOOR ordinal scale includes four possible outcomes: treatment failure, infectious complications, antibiotic-associated adverse events and death. The ordinal scale comprises five levels: levels 1-4 are defined by survival at 30 days and the presence of either none, one, two or three of three possible outcomes; level 5 indicates death before 30 days. A DOOR analysis estimates the probability that overall outcomes in any given subject in one group are overall superior to those in a random subject from the other treatment group; probabilities \>50% reject the null hypothesis.
Time frame: From enrollment to 30 days post enrollment
90-day hospital-free days alive
Number of days the patient is alive and out of the hospital
Time frame: From enrollment to 90 days after enrollment
30-day all cause mortality
Number of deaths from any cause within 30 days after enrollment
Time frame: From enrollment to 30 days after enrollment
90-day all-cause mortality
Number of deaths from any cause within 90 days after enrollment
Time frame: From enrollment to 90 days after enrollment
30-day bacteremia-free days
Number of days without bacteremia within 30 days after enrollment
Time frame: From enrollment to 30 days after enrollment
Length of stay
Number of days in the hospital following enrollment
Time frame: Measured at the time of hospital discharge, up to 30 days after enrollment
Total hospital direct costs
Total financial charges incurred by a patient during their hospitalization
Time frame: Measured at the time of hospital discharge, up to 30 days after enrollment
Total inpatient antibiotic cost
Total cost of all antibiotics received by a patient while hospitalized
Time frame: Measured at the time of hospital discharge, up to 30 days after enrollment
Combination antibiotic days
Number of days a patient receives combination antibiotic therapy (CAT) as defined in protocol, instead of antibiotic monotherapy (AM)
Time frame: Measured from the time of enrollment until study day 7, death, or hospital discharge
Antibiotic-associated adverse events
Number and type of patient adverse events definitively associated with the receipt of antibiotics while hospitalized
Time frame: From enrollment to 30 days after enrollment
Clostridioides difficile infection
Presence of infection with Clostridioides difficile while hospitalized
Time frame: From enrollment to 30 days after hospital discharge
Plan to share: Yes — In order to protect patient privacy and comply with relevant regulations, identified data will be unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org
Time frame: Data sharing will be available six months after anticipated enrollment completion, estimated August 2029, for a period to be determined by the Intermountain Office of Research and IRB
Access criteria: Will be determined on an individual basis, upon request to the IH Office of Research.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intermountain Health Care, Inc. →